Table 7.
INSTI Resistance Mutations and Estimated INSTI Resistance Levels
| SID | Sanger and NGS | Sanger alone | NGS alone | Sanger score → NGS score |
||
|---|---|---|---|---|---|---|
| DTG | EVG | RAL | ||||
| Samples for which NGS reported higher levels of drug resistance for one or more INSTIs | ||||||
| 103_IN | E138EK (5.5%) | 1 → 2 | 1 → 3 | 1 → 3 | ||
| 281_IN | T66I, E92Q | G163GR (5.6%) | 3 | 5 | 4 → 5 | |
| Samples for which Sanger or NGS detected different DRMs, but for which levels of INSTI resistance were the same | ||||||
| 38_IN | G140C, Q148R | G163GR (6.5%) | 4 | 5 | 5 | |
Predicted levels of drug resistance according to the HIVdb genotypic resistance interpretation system: susceptible (1); potential low-level resistance (2); low-level resistance (3); intermediate resistance (4); high-level resistance (5). Percent mixtures are shown in parentheses. All samples listed in this table are subtype B.
DRM, drug resistance mutation; DTG, dolutegravir; EVG, elvitegravir; INSTI, integrase strand transfer inhibitor; NGS, next-generation sequencing; PR, protease; RAL, raltegravir; RT, reverse transcriptase; SID, sample ID.